Vascular disruption and blood–brain barrier dysfunction in intracerebral hemorrhage

Table 2 Current and recently (2010 and later) finished clinical trials for treating ICH ^#

Intervention	Study name	Clinical trial #	Target	Outcome
Surgical Evacuation	STICH II		Multiple	No benefit [140]
Surgical Evacuation/tPA	MISTIE III	NCT01827046	Multiple	Ongoing
Blood pressure lowering agents	ATACH-II	NCT01176565	Hematoma expansion	Ongoing
Blood pressure lowering agents	INTERACT2	NCT00716079	Hematoma expansion	Inconclusive*[43]
Blood pressure lowering agents	ICH-ADAPT	NCT00963976	Hematoma expansion	Ongoing
Factor VIIa (for spot sign patients)	SPOTLIGHT	NCT01359202	Hematoma expansion	Ongoing
Factor VIIa (for spot sign patients)	STOP IT	NCT00810888	Hematoma expansion	Ongoing
Factor VIIa (reversal anticoagulants)		NCT00770718	Hematoma expansion	Terminated (poor recruitment)
Platelet Transfusion		NCT00699621	Hematoma expansion	Ongoing
Pioglitazone	SHRINC	NCT00827892	Hematoma resolution	Ongoing
Deferoxamine	iDEF	NCT02175225	Iron toxicity	Ongoing
Minocycline	MACH	NCT01805895	Inflammation	Ongoing
Simvastatin		NCT00718328	Multiple	Terminated (poor recruitment)
Fluoxetine		NCT01737541	Motor recovery	Ongoing
Albumin		NCT00990509	Multiple	Terminated (PI move)
Hypothermia		NCT01866384	Multiple	Ongoing
Ibuprofen		NCT01530880	Fever prevention	Ongoing

Details on clinical trials can be found from the NIH (http://www.clinicaltrials.gov) and The Internet Stroke Center (http://www.strokecenter.org/trials/).
^#For older clinical trials, the reader is referred to Keep et al. [5].
*The effect of acute blood pressure lowering did not quite reach statistical significance in the phase 3 INTERACT2 trial.

ISSN: 2045-8118